Scientists discover gene responsible for rare, inherited eye disease
Ophthalmic images from five of the patients in the study demonstrate significant variability in the forms of retinal dystrophy. Credit: Bin Guan, Ph.D.

Scientists at the National Institutes of Health (NIH) and their colleagues have identified a gene responsible for some inherited retinal diseases (IRDs), which are a group of disorders that damage the eye’s light-sensing retina and threaten vision.

Though IRDs affect more than 2 million people worldwide, each individual disease is rare, complicating efforts to identify enough people to study and conduct clinical trials to develop treatment. The study’s findings were published in JAMA Ophthalmology.

In a small study of six unrelated participants, researchers linked the gene UBAP1L to different forms of retinal dystrophies, with issues affecting the macula, the part of the eye used for central vision such as for reading (maculopathy), issues affecting the cone cells that enable color vision (cone dystrophy) or a disorder that also affects the rod cells that enable night vision (cone-rod dystrophy). The patients had symptoms of retinal dystrophy starting in early adulthood, progressing to severe vision loss by late adulthood.

“The patients in this study showed symptoms and features similar to other IRDs, but the cause of their condition was uncertain,” said Bin Guan, Ph.D., chief of the Ophthalmic Genomics Laboratory at NIH’s National Eye Institute (NEI) and a senior author of the report.

“Now that we’ve identified the causative gene, we can study how the gene defect causes disease and, hopefully, develop treatment.”

Identifying the UBAP1L gene’s involvement adds to the list of more than 280 genes responsible for this heterogeneous disease.

“These findings highlight the importance of providing genetic testing to our patients with retinal dystrophy, and the value of the clinic and lab working together to better understand retinal diseases,” said co-senior author on the paper, Laryssa A. Huryn, M.D., an ophthalmologist at the NEI, part of the National Institutes of Health.

Genetic evaluation of the six patients revealed four variants in the UBAP1L gene, which encodes for a protein that is abundantly expressed in retina cells, including retinal pigment epithelium cells and photoreceptors. More research is needed to understand the UBAP1L gene’s exact function, but scientists were able to determine that the identified variants likely cause the gene to produce protein that lacks function.

Future studies will also be informed by the fact that variants appear to be distinctive to geographic regions. Five of the six families in this study were from South or Southeastern Asia, or Polynesia, regions that have been underrepresented in genetic studies.

The research was co-led by investigators at Moorfields Eye Hospital and University College London.

More information:
Biallelic loss-of-function variants in UBAP1L and nonsyndromic retinal dystrophies, JAMA Ophthalmology (2024). DOI: 10.1001/jamaophthalmol.2024.3836

Citation:
Scientists discover gene responsible for rare, inherited eye disease (2024, September 26)
retrieved 28 September 2024
from https://medicalxpress.com/news/2024-09-scientists-gene-responsible-rare-inherited.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Before you post, please prove you are sentient.

what is 7 plus 9?

Explore More

Preclinical tests show mRNA-based treatments effective for blinding condition

This infographic describes the mechanism of the mRNA-based RUNX1 therapy when it gets introduced into the PVR cell. Credit: Mass Eye and Ear A preclinical study by Mass Eye and

Sustained visual improvements in LHON patients treated with AAV gene therapy

Credit: CC0 Public Domain A multinational study led by the LHON Study Group has revealed sustained visual improvements and a favorable safety profile five years following lenadogene nolparvovec gene therapy

Just a moment…

Just a moment… Enable JavaScript and cookies to continue This request seems a bit unusual, so we need to confirm that you’re human. Please press and hold the button until